<DOC>
	<DOCNO>NCT01982318</DOCNO>
	<brief_summary>The objective study assess efficacy safety VitroGro® combine standard care treatment Venous Leg Ulcers ( VLUs ) compare Placebo standard care course 8-week treatment phase .</brief_summary>
	<brief_title>A Prospective Randomized , Double-Blind , Placebo-Controlled Trial Comparing VitroGro® ECM Placebo Patients With Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Abbreviations : Study Ulcer : SU Postdebridement : PD Potential subject require meet follow criterion enrollment study subsequent randomization . 1 . 18≤ year old . 2 . Ankle Brachial Pressure Index ≥0.80 . ( Calculations make use measurement posterior tibial &amp; dorsalis pedis artery &amp; arm ) . 3 . Presence venous leg ulcer extend full thickness skin , muscle , tendon , bone . The large ulcer designate SU one include study . If ulcerations present leg must 2 cm apart SU . 4 . Venous disease confirm Doppler ultrasound demonstrate reflux &gt; 0.5 second saphenous ( great small ) , calf perforators deep venous system . Subjects prior venous surgery may include still demonstrate significant reflux remain venous segment SU continue suffer poor heal venous hypertension . 5 . SU present 1 ≤ x ≤ 12 month prior initial screen visit , exclude undergone 12 month continuous high strength compression therapy duration . 6 . SU 2.5 ≤ x ≤ 20 cm2 T1 visit ( PD ) . 7 . SU clean , granulate base free adherent slough T1 visit ( PD ) . 8 . In case female patient childbearing potential , willingness use acceptable method contraception . A urine pregnancy test T1 visit must administer , must negative inclusion . 9 . Understanding willingness patient participate clinical study ability comply study procedure study visit schedule . 10 . Reading , approval , signature patient IRB/IEC ICF screening procedure undertake . Potential subject meet follow criterion exclude enrollment subsequent randomization : 1 . Ulcer ( ) deem Investigator cause medical condition venous insufficiency . These may include , limited : ulceration due fungal , malignant , diabetic , and/or arterial insufficiency cause . 2 . Ulcer exhibit clinical sign symptom infection S1 T1 . The infection treat &amp; afterward patient may reassess eligibility study reentry . 3 . Known allergy protocolstipulated treatment procedure nontolerance multilayer compression therapy . 4 . Ulcer , opinion Investigator , suspicious cancer . 5 . A history 2 week treatment immunosuppressant ( include systemic corticosteroid ) , cytotoxic chemotherapy , application topical steroid ulcer surface within 1 month prior S1 , treatment medication screen , anticipated requirement medication course study . 6 . Treatment investigational drug ( ) therapeutic device ( ) within 30 day precede S1 ; anticipate use therapy course study . 7 . Malignant disease remission 5 year , basal cell squamous cell carcinoma skin medically surgically treat without evidence metastasis . 8 . History radiation SU site . 9 . As determined medical history , presence one medical condition include renal , hepatic , hematologic , active autoimmune immune disease , opinion Investigator , would make subject inappropriate candidate ulcer heal study . 10 . Known history AIDS history HIV infection . 11 . Previous participation VitroGro® ECM trial within past 6 month . 12 . SU previously treat tissue engineer material scaffold material within 30 day prior S1 . 13 . SU opinion Investigator might require negative pressure wound therapy hyperbaric oxygen course trial . 14 . Presence condition ( ) seriously compromise ( ) subject 's ability complete study , know history poor adherence medical treatment . 15 . NYHA Class III IV congestive heart failure ( CHF ) , define follow criterion : Class III : Symptoms moderate exertion Class IV : Symptoms rest 16 . Uncontrolled Diabetes Mellitus , measure HbA1c &gt; 10 % . 17 . Ulcer dorsum foot 50 % ulcer malleolus exclude . 18 . Pregnancy breastfeed . 19 . Increase decrease &gt; 30 % SU surface area T1 visit ( PD ) compare SU surface area measure S1 visit ( PD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Venous Leg Ulcer</keyword>
	<keyword>Leg Ulcer</keyword>
	<keyword>Venous Hypertension</keyword>
	<keyword>Venous Reflux</keyword>
	<keyword>Deep Venous System</keyword>
	<keyword>Chronic leg ulceration</keyword>
	<keyword>Calf perforator</keyword>
</DOC>